What’s next for targeting cancer DNA repair with PARP inhibitors?
DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat cancers with existing defects in DNA repair, such as BRCA mutant cancers.
DDR inhibitors block critical DNA repair pathways that these cancers rely on to repair their DNA as they grow and divide. Other important DDR players being targeted by researchers are ataxia telangiectasia and Rad3-related...
ARTEMIS clinical trial offers triple-negative patients personalized therapy
Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single disease...
Possible side effects of immunotherapy — and how to handle them
Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma, non-small cell...